IVIS LUMINA II XR FOR OPTICAL IMAGING OF RADIOPHARMACEUTICALS

描述（由申请人提供）：在过去的十年中，生物发光报告系统的使用在研究应用中呈指数级增长。因此，生物发光成像（BLI）已成为华盛顿大学和世界各地分子成像不可缺少的组成部分。使用多种成像模式来解决生物学问题，现在是司空见惯的成像研究实验室。在BLI的新转折中，Robertson等人（Phys Med Biol 2009）表明，IVIS 100和200 BLI扫描仪（现在分别被IVIS Lumina和Spectrum所取代）可以持续地检测到来自18F和13N核素的切伦科夫光信号。当带电粒子以超过光速的速度穿过绝缘介质时，就会产生切伦科夫辐射。切伦科夫辐射是从近紫外到可见光谱的连续光谱中产生的，其分布与波长的大小成反比。“切伦科夫发光成像”（CLI）被描述为使用发射正电子或负电子的放射性药物对小鼠进行体内成像，并与18FDG PET在检测皮下肿瘤植入物方面表现出良好的相关性。独立地，另一组研究人员（Liu et al ., PLoS One 2010）用额外的正电子和负电子发射器验证了CLI。我们建议购买IVIS Lumina II XR (Caliper Life Sciences, Inc.)，这是一种能够检测发光、荧光和x射线发射的新一代分子成像工具。引入伴随生物发光的x射线成像，通过将生物发光信号置于解剖学背景下，提供了额外的分辨率。我们对IVIS Lumina II XR的预期用途可以分为三大类：1)涉及CLI的项目；2)涉及BLI和荧光成像监测放射药物靶向放疗的项目；3)传统BLI实验。CLI应用将侧重于开发新型PET放射性药物的高通量评估。华盛顿大学拥有理想的师资和资源，可以更充分地开发新的CLI技术。我们有8个nih资助的用户开发放射性药物和多模态显像剂，其中一个（Dr. Tai）开发PET/光学仪器。吴现有的教师、设施和资源，加上强有力的制度支持，将确保IVIS Lumina II XR将被进一步利用和开发，用于新的尖端技术，这将使吴作为一所大学，以及整个成像界受益。

DESCRIPTION (provided by applicant): Throughout the last decade, the use of bioluminescence reporter systems has seen an exponential growth in research applications. As a result, bioluminescence imaging (BLI) has become an indispensible component of molecular imaging at Washington University and throughout the world. The use of multiple imaging modalities to address biological questions is now commonplace in imaging research laboratories. In a new twist on BLI, Robertson et al. (Phys Med Biol 2009) showed that the IVIS 100 and 200 BLI scanners (which have now been replaced by the IVIS Lumina and Spectrum, respectively) could consistently detect a Cerenkov light signal from 18F and 13N nuclides. Cerenkov radiation is produced when a charged particle travels with a velocity that exceeds the speed of light through an insulating medium. Cerenkov radiation is produced in a continuous spectrum from the near ultraviolet through the visible spectrum, distributed inversely proportional to the squire of the wavelength. "Cerenkov luminescence imaging" (CLI) was described for in vivo imaging of mice with radiopharmaceuticals that emit either positron or beta minus, and demonstrated a good correlation with 18FDG PET in detecting a subcutaneous tumor implant. Independently, another group of researchers (Liu et al, PLoS One 2010) validated CLI with additional positron and beta minus emitters. We propose the purchase of an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. The introduction of concomitant x-ray imaging with bioluminescence provides an additional degree of resolution by putting the bioluminescence signal in anatomical context. Our intended use of the IVIS Lumina II XR can be separated into three general categories: 1) projects that involve CLI; 2) projects that involve BLI and fluorescence imaging for monitoring targeted radiotherapy with beta emitting radiopharmaceuticals; and 3) traditional BLI experiments. The CLI applications will focus on developing high throughput assessment of novel PET radiopharmaceuticals. Washington University has the ideal faculty and resources to more fully develop the new CLI technology. We have 8 NIH-funded users developing radiopharmaceuticals and multimodality imaging agents, and one of them (Dr. Tai) develops PET/optical instrumentation. The existing faculty, facilities and resources at WU, together with strong institutional support, will ensure that the IVIS Lumina II XR will be utilized and developed further for a new, cutting-edge technology, which will benefit WU as a university, as well as the imaging community as a whole. Public Health Relevance: Molecular imaging is a science involving non-invasive imaging of molecular processes. We propose to purchase an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. Washington University will use the instrument primarily for "Cerenkov luminescence imaging" a cutting-edge technology designed for high throughput radiopharmaceutical development.